Celeris Therepeutics is a deep learning company that uses innovative, computer-based methods to degrade undruggable targets. Their platform Celeris One exploits the potential of degrader technologies with accurate predictions of biomolecular interactions and the expansion of chemical space. Deep learning serves as an enabler.
SiPhox’s fully chip-based diagnostic solution combines state-of-the art integrated photonics, electronics and microfluidics in order to unlock At-Home and Point-of-Care multiplexed proteomics. Using the cutting-edge optical chips that power the internet today, SiPhox is bringing the benefits of Moore’s law to biotechnology.
Maxwell Biosciences is a company developing a novel biomimetic small molecule drug class intended to target the host-produced viral envelope membrane. The company's virucidal drugs mimic natural antiviral peptides, destroy a broad range of viruses directly, irreversibly and permanently inactivating the virus itself.
Occuity specialises in the research, design and production of non-contacting optical instruments for use in healthcare diagnostics and monitoring. Occuity’s meters work by shining light into the eye and analysing the return signal. This enables direct specialized measurements of the eye, but also more general health conditions such as diabetes and Alzheimer’s Disease to be monitored.
Pano Therapeutics focuses on the clinical development of patented small molecule drugs targeting mitochondrial ion channels addressing a constellation of complex disease states. Utilizing novel ion channel target associated with Metformin’s mitochondrial mechanism of action identified by Pano's scientific founder.
Juvena Therapeutics is a biopharma startup developing protein-based tissue regeneration therapeutics. The company's platform screens restored muscle stem cell functions to produce protein-based therapeutics, which promote tissue regeneration in the elderly. Initially targeting sarcopenia and muscle regeneration.
Remedium Bio is a biotechnology company developing novel gene therapies for a broad range of highly debilitating diseases. Their lead candidate is a first-in-class single-injection, potentially disease-modifying treatment for Osteoarthritis, a progressive, debilitating disease with no approved treatments capable of slowing or reversing disease progression.
Embrace Prevention Care provides Personal Prevention Care to older adults with heart failure and other chronic conditions to prevent hospitalizations. By helping patients take the right actions and medications to follow their care plans, they stay independent longer and safely age in place.
Novos Labs develops the most thoroughly formulated longevity products available, backed by world-renowned scientists from Harvard University, MIT, University of Washington, the Salk Institute, and more. Flagship product NOVOS Core is a once-daily sachet with 12 synergistic ingredients aiming to slow aging that leverages current science to deliver the most effective longevity product on the market.